RU58841 is not FDA approved, and users are discussing its availability and legitimacy in India, with some mentioning brands like Vantanex and Capomil. One user warns about the risk of gyno from RU58841, advising to stop use at the first sign of sensitivity.
The user experienced severe side effects when using topical Dutasteride and RU58841 together and is considering using them at different times of the day. They are seeking advice on whether this approach might reduce side effects.
RU58841, a hair loss treatment, is available on Amazon, but its legitimacy is questioned due to sketchy reviews and lack of lab reports. Some users report seeing results, while others experience negative side effects.
The conversation is about a person's experience with hair loss treatment using finasteride and minoxidil for a year, and then seeing improved results after adding RU58841. They suggest shaving the head before starting RU58841 to better track progress.
The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.
Dutasteride is recommended over finasteride for severe hair loss, despite potential side effects. The original poster has been using various treatments for four months and is considering adding copper tripeptide-1.
A user is considering buying RU58841 powder from Aliexpress to mix with Minoxidil for hair loss treatment. Another user warns about the safety concerns of RU58841, especially from unreliable sources, and suggests trying finasteride, oral Minoxidil, and dutasteride first.
The user is using 0.1% dutasteride, 1% minoxidil with 2% procapil and 0.005% caffeine in the morning, and 1% minoxidil with 2% procapil and 0.01% tretinoin at night. They are concerned about the solution vehicle's effectiveness in preventing systemic absorption and ensuring the products stay around the hair follicles.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
The conversation is about using topical valproic acid (VPA) for hair loss, focusing on its application method, usage frequency, and combination with other treatments like micro-needling. No specific experiences with VPA were shared.
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
A user is seeking advice on treating a chin scar with Verteporfin, noting that higher doses were more effective. Another user responds that they do not use it, without providing further explanation.
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.
A user discusses a topical treatment combining Minoxidil, Betamethasone Valerate, Canrenone, Finasteride, and Dutasteride for hair loss. The treatment is RX-only and provided by a dermatologist.
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
The conversation discusses disappointment in Verteporfin for hair loss treatment, with a mention of an upcoming trial by Dr. Bisanga. No specific treatments were confirmed as used by the original poster.
The conversation is about a user obtaining a compounded treatment for hair loss, including 0.1% latanoprost, 0.2% melatonin, and 1% cetirizine. The user also uses 2.5 mg dutasteride, 5 mg minoxidil, and RU58841 daily, and is at Norwood 2.
Veradermics' phase 2 trial of slow-release oral minoxidil shows promising hair regrowth with minimized side effects, gaining significant attention and funding. PP405 is also noted for its potential as a side-effect-free alternative.
Adderall and Vyvanse may contribute to hair loss by stressing the dopamine system and increasing cortisol levels. Users discuss potential treatments like Minoxidil, finasteride, and RU58841 for managing hair loss.
A user was prescribed betamethasone dipropionate spray for a receding hairline, which caused skin peeling and depigmentation. They stopped using it and are considering alternatives like BPC-157/TB-500 for healing.
The user experienced sexual side effects from finasteride and switched to using only topical minoxidil without side effects. They are seeking alternatives to finasteride, such as topical finasteride, to maintain hair without adverse effects.
The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.
The conversation discusses the effectiveness of Vichy Dercos Aminexil Clinical R.E.G.E.N. Booster for hair shedding and thinning. The main ingredient, Aminexil, is compared to Minoxidil, and the user seeks real experiences to determine its efficacy.